tiprankstipranks
Trending News
More News >

Broncus Holding Corp. Reports 2024 Results and Clinical Progress

Story Highlights
Broncus Holding Corp. Reports 2024 Results and Clinical Progress

Don’t Miss TipRanks’ Half-Year Sale

Broncus Holding Corp. ( (HK:2216) ) has issued an announcement.

Broncus Holding Corporation announced its annual results for 2024, reporting a 21% decrease in revenue and a 46% reduction in losses compared to the previous year. Despite financial challenges, the company made significant strides in clinical progress, with key developments in their flagship products demonstrating promising clinical results. These advancements are expected to enhance Broncus’s market position and provide strong evidence supporting the efficacy and safety of its innovative respiratory treatments.

More about Broncus Holding Corp.

Broncus Holding Corporation operates in the medical industry, focusing on innovative diagnostic and therapeutic solutions for respiratory diseases. The company is known for its flagship products, including the Transbronchial Radiofrequency Ablation System and InterVapor, which target lung tumors and emphysema, respectively.

YTD Price Performance: 50.85%

Average Trading Volume: 1,961,965

Technical Sentiment Signal: Sell

Current Market Cap: HK$468M

For detailed information about 2216 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1